logo
Plus   Neg
Share
Email

Gilead Sciences Q4 Profit Misses Estimates

Gilead Sciences, Inc. (GILD) reported fourth-quarter non-GAAP net income per share of $1.30, compared to $1.44, a year ago. On average, 24 analysts polled by Thomson Reuters expected the company to report profit per share of $1.67, for the quarter. Analysts' estimates typically exclude special items.

Fourth-quarter total revenues were $5.9 billion compared to $5.8 billion, last year. Analysts expected revenue of $5.71 billion for the quarter. Total product sales were $5.8 billion, compared to $5.7 billion, prior year. HIV product sales were $4.6 billion compared to $4.1 billion, last year.

For full year 2020, the company projects: non-GAAP earnings per share in a range of $6.05 - $6.45; and product sales in a range of $21.80 billion to $22.20 billion. Analysts polled by Thomson Reuters expect the company to report profit per share of $7.01.

Gilead Sciences also announced its Board has declared an increase of 8% in the quarterly cash dividend, beginning in the first quarter of 2020. The increase will result in a quarterly dividend of $0.68 per share of common stock. The dividend is payable on March 30, 2020, to stockholders of record at the close of business on March 13, 2020.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
WeWork's parent company, We Company, said it has filed a lawsuit against Japanese conglomerate SoftBank Group Corp. for failing to consummate a $3 billion tender offer for the company's shares. After WeWork's failed attempt at an initial public offering last year, SoftBank acquired a majority stake in the office sharing company in a bailout, severing most ties with WeWork co-founder Adam Neumann. Walgreens is expanding drive-thru testing for the coronavirus to fifteen new locations in seven states across the U.S. later this week. They include Arizona, Florida, Illinois, Kentucky, Louisiana, Tennessee and Texas. The drive-thru locations are part of Walgreens' collaboration with the administration, federal health agencies, and state and local authorities to expand access to COVID-19 testing. iPhone assembler Foxconn, otherwise known as Hon Hai Precision Industry Co. Ltd., is reportedly set to start manufacturing ventilators in the United States in partnership with medical device firm Medtronic plc., as the U.S. braces for the cornavirus (COVID-19) infection peak. Taiwan-based Foxconn will start manufacturing ventilators at its Wisconsin factory within the next four to six weeks.
Follow RTT
>